Phase II trial of continuous low-dose temozolomide (TMZ) for recurrent malignant glioma (MG) with and without prior exposure to bevacizumab (BEV)

被引：1
|
作者：
Khasraw, M. [1 ]
Abrey, L. E. [1 ]
Lassman, A. B. [1 ]
Hormigo, A. [1 ]
Nolan, C. [1 ]
Gavrilovic, I. T. [1 ]
Mellinghoff, I. K. [1 ]
Reiner, A. S. [1 ]
DeAngelis, L. M. [1 ]
Omuro, A. M. [1 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.2065
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
2065
引用
收藏
页数：1
相关论文
共 50 条
  • [1] PHASE II TRIAL OF CONTINUOUS LOW-DOSE TEMOZOLOMIDE (TMZ) FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA (MG) WITH AND WITHOUT PRIOR EXPOSURE TO BEVACIZUMAB (REV)
    Khasraw, Mustafa
    Abrey, Lauren E.
    Lassman, Andrew B.
    Hormigo, Adilia
    Nolan, Craig
    Gavrilovic, Igor T.
    Mellinghoff, Ingo K.
    Reiner, Anne S.
    DeAngelis, Lisa
    Omuro, Antonio M.
    NEURO-ONCOLOGY, 2010, 12 : 72 - 72
  • [2] Phase II trial of continuous low-dose temozolomide for patients with recurrent malignant glioma
    Omuro, Antonio
    Chan, Timothy A.
    Abrey, Lauren E.
    Khasraw, Mustafa
    Reiner, Anne S.
    Kaley, Thomas J.
    DeAngelis, Lisa M.
    Lassman, Andrew B.
    Nolan, Craig P.
    Gavrilovic, Igor T.
    Hormigo, Adilia
    Salvant, Cynthia
    Heguy, Adriana
    Kaufman, Andrew
    Huse, Jason T.
    Panageas, Katherine S.
    Hottinger, Andreas F.
    Mellinghoff, Ingo
    NEURO-ONCOLOGY, 2013, 15 (02) : 242 - 250
  • [3] PHASE II TRIAL OF CONTINUOUS LOW-DOSE TEMOZOLOMIDE FOR PATIENTS WITH RECURRENT MALIGNANT GLIOMA
    Ney, Douglas
    Deangelis, Lisa
    Nolan, Craig
    Gavrilovic, Igor
    Hormigo, Adilia
    Lassman, Andrew
    Abrey, Lauren
    NEURO-ONCOLOGY, 2008, 10 (05) : 831 - 831
  • [4] PHASE II TRIAL OF LOW-DOSE CONTINUOUS (METRONOMIC) TREATMENT OF TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA
    Nam, Do-Hyun
    Kong, Doo-Sik
    Lee, Jung-Il
    Park, Kwan
    Kim, Jong Hyun
    NEURO-ONCOLOGY, 2008, 10 (05) : 841 - 841
  • [5] PHASE II TRIAL OF LOW-DOSE CONTINUOUS (METRONOMIC) TREATMENT OF TEMOZOLOMIDE FOR RECURRENT GLIOBLASTOMA
    Kim, Jong Hyun
    Kong, Doo-Sik
    Lee, Jung-Il
    Nam, Do-Hyun
    NEURO-ONCOLOGY, 2009, 11 (06) : 909 - 909
  • [6] Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma
    Kong, Doo-Sik
    Lee, Jung-Il
    Kim, Jong Hyun
    Kim, Sung Tae
    Kim, Won Seog
    Suh, Yeon-Lim
    Dong, Seung Myung
    Nam, Do-Hyun
    NEURO-ONCOLOGY, 2010, 12 (03) : 289 - 296
  • [7] Phase II Trial of Continuous Dose-Intense Temozolomide in Recurrent Malignant Glioma: RESCUE Study
    Perry, James R.
    Belanger, Karl
    Mason, Warren P.
    Fulton, Dorcas
    Kavan, Petr
    Easaw, Jacob
    Shields, Claude
    Kirby, Sarah
    Macdonald, David R.
    Eisenstat, David D.
    Thiessen, Brian
    Forsyth, Peter
    Pouliot, Jean-Francois
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) : 2051 - 2057
  • [8] THE TEMOZOLOMIDE RESCUE STUDY: A PHASE II TRIAL OF CONTINUOUS (28/28) DOSE-INTENSE TEMOZOLOMIDE (TMZ) AFTER PROGRESSION ON CONVENTIONAL 5/28 DAY TMZ IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA
    Perry, J.
    Mason, W.
    Belanger, K.
    Kavan, P.
    Fulton, D.
    Easaw, J.
    Kirby, S.
    Macdonald, D.
    Shields, C.
    Pouliot, J. F.
    NEURO-ONCOLOGY, 2008, 10 (06) : 1063 - 1063
  • [9] The temozolomide RESCUE study: A phase II trial of continuous (28/28) dose-intense temozolomide (TMZ) after progression on conventional 5/28 day TMZ in patients with recurrent malignant glioma
    Perry, J. R.
    Mason, W. P.
    Belanger, K.
    Kavan, P.
    Fulton, D.
    Easaw, J.
    Kirby, S.
    Macdonald, D.
    Shields, C.
    Pouliot, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [10] A phase II study of extended low-dose temozolomide in recurrent malignant gliomas
    Khan, RB
    Raizer, JJ
    Malkin, MG
    Bazylewicz, KA
    Abrey, LE
    NEURO-ONCOLOGY, 2002, 4 (01) : 39 - 43
12345